Abcodia Inc., a British company that manufactures a controversial ovarian cancer screening test, said it will temporarily suspend the availability of the product in the United States.
Research Project Grant funding at NCI has increased 25 percent, from $400 million in 2013 to $500 million in 2015, NCI Acting Director Douglas Lowy said to the National Cancer Advisory Board Sept. 7.
A brief consult with an undergraduate earning a B or above in Statistics 101 might have acquainted Spectrum Pharmaceuticals executives with all the science that would have saved them from a devastating encounter with an FDA advisory committee.
Vice President Joe Biden Sept. 16 announced a series of initiatives to improve the safety, accessibility, and impact of clinical research—one of the central goals of the National Cancer Moonshot Initiative.
FDA has recommended against the use of ovarian cancer screening tests, regardless of risk level.
Robert Westscott “Dr. Bob” Frelick died Sept. 1, 2016. He passed away in his sleep after an accident and short illness. He was 96.
NCI will urge increased and sustained appropriations for carrying out ten recommendations put forward by the Blue Ribbon Panel, the institute's scientific advisory panel to the National Cancer Moonshot Initiative.
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
Amgen Inc. agreed to pay $95 million to settle a class action suit filed by investors who bought the company's securities between April 2004 and May 2007.
Roger Tsien, co-winner of the 2008 Nobel Prize in chemistry and professor of pharmacology, chemistry and biochemistry at University of California San Diego School of Medicine for 27 years, died Aug. 24 in Eugene, Ore. He was 64.
